A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of NMD670 over 21 days in Ambulatory Adult Patients with Charcot-Marie-Tooth Disease Type 1 and Type 2

This study is a clinical trial, which means it's a careful way to test new treatments. The treatment being tested is a medicine called NMD670. It's for adults who have a condition called Charcot-Marie-Tooth disease (CMT), specifically types 1 and 2. CMT is a group of inherited conditions that affect the nerves, leading to muscle weakness and problems with feeling in the arms and legs. There isn't a cure for CMT yet, so researchers are always looking for new ways to help manage the condition.

The study aims to see if NMD670 can help people with CMT walk better. To do this, some participants will receive NMD670, and others will receive a placebo. A placebo looks just like the real medicine but contains no active ingredients. This helps researchers figure out if any changes are due to the medicine itself or other factors. Both the participants and the study team won't know who is getting which treatment until the study is over – this is called 'double-blind'.

This is a 'Phase 2a' study, which means it's an early stage of testing. The main thing they'll be measuring is how much further people can walk in a 6-minute walking test, comparing those who took NMD670 to those who took the placebo. They'll also be carefully checking for any side effects to make sure the medicine is safe and tolerated well over the 21 days of treatment. Studying NMD670 is important because it could potentially offer a new way to help people with CMT manage their symptoms and improve their daily lives.